Fabrice Barlési

71.2k total citations · 17 hit papers
570 papers, 22.1k citations indexed

About

Fabrice Barlési is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Fabrice Barlési has authored 570 papers receiving a total of 22.1k indexed citations (citations by other indexed papers that have themselves been cited), including 412 papers in Oncology, 400 papers in Pulmonary and Respiratory Medicine and 73 papers in Cancer Research. Recurrent topics in Fabrice Barlési's work include Lung Cancer Treatments and Mutations (334 papers), Lung Cancer Research Studies (163 papers) and Cancer Immunotherapy and Biomarkers (145 papers). Fabrice Barlési is often cited by papers focused on Lung Cancer Treatments and Mutations (334 papers), Lung Cancer Research Studies (163 papers) and Cancer Immunotherapy and Biomarkers (145 papers). Fabrice Barlési collaborates with scholars based in France, United States and Spain. Fabrice Barlési's co-authors include Martin Reck, Denis Moro‐Sibilot, Silvia Novello, Delvys Rodríguez‐Abreu, Federico Cappuzzo, Francesco Orlandi, Mark A. Socinski, Solange Peters, Robert M. Jotte and Naoyuki Nogami and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Communications.

In The Last Decade

Fabrice Barlési

540 papers receiving 21.7k citations

Hit Papers

Atezolizumab for First-Li... 2012 2026 2016 2021 2018 2016 2012 2019 2016 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
    2018 2.6k citations Fabrice Barlési, Martin Reck et al. profile →
  2. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2016 1.9k citations Silvia Novello, Fabrice Barlési et al. Annals of Oncology profile →
  3. Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
    2012 816 citations Fabrice Barlési, Martin Reck et al. Journal of Clinical Oncology profile →
  4. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
    2019 688 citations Martin Reck, Makoto Nishio et al. profile →
  5. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
    2016 612 citations David Planchard, Benjamin Besse et al. profile →
  6. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
    2012 500 citations Martin Reck, Fabrice Barlési et al. Annals of Oncology profile →
  7. Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
    2013 489 citations Julien Mazières, Solange Peters et al. Journal of Clinical Oncology profile →
  8. Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
    2013 370 citations Maciej Krzakowski, Fabrice Barlési et al. Journal of Clinical Oncology profile →
  9. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
    2017 354 citations Fabrice Barlési, P. Fournel et al. profile →
  10. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
    2018 336 citations Fabrice Barlési, Marina Chiara Garassino et al. profile →
  11. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
    2016 334 citations David Planchard, Julien Mazières et al. profile →
  12. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
    2021 316 citations Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology profile →
  13. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
    2022 296 citations Byoung Chul Cho, Fabrice Barlési et al. profile →
  14. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
    2020 290 citations Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology profile →
  15. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
    2021 196 citations Martin Reck, Marina Chiara Garassino et al. Annals of Oncology profile →
  16. Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
    2021 196 citations Mihaela Aldea, Aurélien Marabelle et al. profile →
  17. Anti-TIGIT therapies for solid tumors: a systematic review
    2023 90 citations Fabrice Barlési et al. ESMO Open profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Fabrice Barlési 15.4k 13.4k 5.1k 3.3k 2.7k 570 22.1k
Martin Reck 17.5k 1.1× 13.7k 1.0× 4.5k 0.9× 3.2k 1.0× 2.7k 1.0× 402 22.9k
Alan Sandler 17.9k 1.2× 15.6k 1.2× 5.9k 1.2× 3.3k 1.0× 2.0k 0.7× 163 23.8k
Mark A. Socinski 15.1k 1.0× 14.6k 1.1× 4.9k 1.0× 3.0k 0.9× 1.7k 0.6× 518 22.3k
Suresh S. Ramalingam 15.5k 1.0× 14.5k 1.1× 8.8k 1.7× 4.2k 1.3× 2.6k 1.0× 593 25.5k
Byoung Chul Cho 13.2k 0.9× 12.9k 1.0× 5.7k 1.1× 3.2k 1.0× 2.0k 0.7× 689 19.8k
Luis Paz‐Ares 13.2k 0.9× 11.4k 0.8× 7.6k 1.5× 4.2k 1.3× 2.2k 0.8× 690 23.0k
Julian R. Molina 10.5k 0.7× 8.2k 0.6× 6.2k 1.2× 3.3k 1.0× 1.9k 0.7× 216 18.3k
Lesley Seymour 13.8k 0.9× 13.6k 1.0× 5.3k 1.0× 3.8k 1.1× 1.2k 0.4× 258 22.2k
David Planchard 11.0k 0.7× 10.0k 0.7× 4.6k 0.9× 3.4k 1.0× 1.1k 0.4× 431 16.5k
Benjamin Solomon 12.7k 0.8× 14.1k 1.1× 6.7k 1.3× 4.3k 1.3× 1.1k 0.4× 415 20.8k

Countries citing papers authored by Fabrice Barlési

Since Specialization
Citations

This map shows the geographic impact of Fabrice Barlési's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabrice Barlési with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabrice Barlési more than expected).

Fields of papers citing papers by Fabrice Barlési

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabrice Barlési. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabrice Barlési. The network helps show where Fabrice Barlési may publish in the future.

Co-authorship network of co-authors of Fabrice Barlési

This figure shows the co-authorship network connecting the top 25 collaborators of Fabrice Barlési. A scholar is included among the top collaborators of Fabrice Barlési based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabrice Barlési. Fabrice Barlési is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Solomon, Benjamin, Yi‐Long Wu, Rafał Dziadziuszko, et al.. (2024). 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo). Annals of Oncology. 35. S775–S775. 1 indexed citations
2.
Dziadziuszko, Rafał, Fabrice Barlési, Jeong Eun Kim, et al.. (2024). Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.. Journal of Clinical Oncology. 42(17_suppl). LBA2509–LBA2509.
3.
Barlési, Fabrice, Enriqueta Felip, Sanjay Popat, et al.. (2024). Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).. Journal of Clinical Oncology. 42(16_suppl). TPS8653–TPS8653. 4 indexed citations
4.
Barlési, Fabrice, Byoung Chul Cho, Sarah B. Goldberg, et al.. (2024). PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncology. 20(29). 2137–2147. 17 indexed citations
5.
Tagliamento, Marco, David Planchard, Fabrice Barlési, et al.. (2024). Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer. Clinical Lung Cancer. 25(8). e482–e486.e3.
6.
Khushalani, Nikhil I., Patrick A. Ott, Robert L. Ferris, et al.. (2024). Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(3). e007364–e007364. 18 indexed citations
7.
Dall’Olio, Filippo Gustavo, Damien Vasseur, Maryam Karimi, et al.. (2023). Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.. Journal of Clinical Oncology. 41(16_suppl). 2516–2516.
8.
Decazes, Pierre, Samy Ammari, Hugues Talbot, et al.. (2023). Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer. Journal for ImmunoTherapy of Cancer. 11(9). e007315–e007315. 9 indexed citations
9.
Zullo, Lodovica, Maria‐Rosa Ghigna, Damien Vasseur, et al.. (2023). 80P Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC). ESMO Open. 8(1). 101890–101890. 1 indexed citations
10.
Ghigna, Maria‐Rosa, Filippo Gustavo Dall’Olio, Martina Mandarano, et al.. (2023). 2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC. Annals of Oncology. 34. S1197–S1198. 1 indexed citations
11.
Tagliamento, Marco, Édouard Auclin, Mihaela Aldea, et al.. (2023). Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. European Journal of Cancer. 182. 107–114. 25 indexed citations
12.
Tagliamento, Marco, Massimo Di Maïo, Jordi Remón, et al.. (2023). Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma. Journal of Thoracic Oncology. 19(1). 166–172. 8 indexed citations
13.
Tselikas, Lambros, Stéphane Champiat, Rahul A. Sheth, et al.. (2021). Interventional Radiology for Local Immunotherapy in Oncology. Clinical Cancer Research. 27(10). 2698–2705. 26 indexed citations
14.
Dziadziuszko, Rafał, Matthew Krebs, Filippo de Braud, et al.. (2021). Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusion–Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 39(11). 1253–1263. 111 indexed citations
15.
Morgan, Gilberto, Evandro de Azambuja, Kevin Punie, et al.. (2021). OncoAlert Round Table Discussions: The Global COVID-19 Experience. JCO Global Oncology. 7(7). 455–463. 6 indexed citations
16.
Remón, Jordi, Benjamin Besse, Alexandra Léary, et al.. (2020). Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial. JTO Clinical and Research Reports. 1(3). 100068–100068. 19 indexed citations
17.
Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2016). Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(8). 1937–1944. 65 indexed citations
18.
Benzekry, Sébastien, Laëtitia Padovani, Christophe Meille, et al.. (2016). Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. Cancer Research. 76(17). 4931–4940. 122 indexed citations
19.
Zimmer, Lisa, Fabrice Barlési, Maria Martinez‐García, et al.. (2014). Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations. Clinical Cancer Research. 20(16). 4251–4261. 59 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Reck Breakdown of academic impact, for papers by Alan Sandler Breakdown of academic impact, for papers by Mark A. Socinski Breakdown of academic impact, for papers by Suresh S. Ramalingam Breakdown of academic impact, for papers by Byoung Chul Cho Breakdown of academic impact, for papers by Luis Paz‐Ares Breakdown of academic impact, for papers by Julian R. Molina Breakdown of academic impact, for papers by Lesley Seymour Breakdown of academic impact, for papers by David Planchard Breakdown of academic impact, for papers by Benjamin Solomon
Rankless by CCL
2026